Market overview
The global point-of-care respiratory diagnostic panels market is worth USD 2.2 bn in 2026 and is forecast to reach USD 4.2 bn by 2036, growing at a 6.5% CAGR. United States is the largest country market and Molecular multiplex panels is the largest by test type segment.
| Scope | Rapid multiplex respiratory tests run at or near the patient, detecting influenza, COVID-19, RSV and other pathogens in a single sample, using molecular and antigen platforms in clinics, hospitals and pharmacies. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 2.1 bn |
| Value 2026 | USD 2.2 bn |
| Value 2036 | USD 4.2 bn |
| CAGR 2026-2036 | 6.5% |
| Volume 2026 | 111 million tests |
| Volume 2036 | 198 million tests |
| Average price 2026 | USD 20.1 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Point-of-Care Respiratory Diagnostic Panels market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 2.2 bn |
| 2027 | USD 2.4 bn |
| 2028 | USD 2.5 bn |
| 2029 | USD 2.7 bn |
| 2030 | USD 2.9 bn |
| 2031 | USD 3.0 bn |
| 2032 | USD 3.2 bn |
| 2033 | USD 3.5 bn |
| 2034 | USD 3.7 bn |
| 2035 | USD 3.9 bn |
| 2036 | USD 4.2 bn |
Point-of-Care Respiratory Diagnostic Panels market segmentation
By test type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Molecular multiplex panels | 36.0% | 49.3% | USD 801 mn | 9.9% |
| Molecular single and dual target | 30.0% | 22.3% | USD 668 mn | 3.4% |
| Rapid antigen multiplex | 24.0% | 20.6% | USD 534 mn | 4.9% |
| Other | 10.0% | 7.8% | USD 223 mn | 3.9% |
By setting
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals and emergency departments | 38.0% | 34.8% | USD 846 mn | 5.6% |
| Physician offices and urgent care | 30.0% | 31.6% | USD 668 mn | 7.0% |
| Retail pharmacies and clinics | 17.0% | 17.1% | USD 378 mn | 6.5% |
| Home and other | 15.0% | 16.5% | USD 334 mn | 7.5% |
By pathogen
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Influenza A and B | 30.0% | 26.0% | USD 668 mn | 5.0% |
| SARS-CoV-2 | 26.0% | 24.0% | USD 579 mn | 5.7% |
| RSV | 14.0% | 18.0% | USD 312 mn | 9.2% |
| Strep and bacterial | 16.0% | 16.0% | USD 356 mn | 6.5% |
| Multi-pathogen syndromic | 14.0% | 16.0% | USD 312 mn | 7.9% |
By format
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cartridge-based | 44.0% | 46.0% | USD 979 mn | 7.0% |
| Lateral flow readers | 30.0% | 26.0% | USD 668 mn | 5.0% |
| Benchtop sample-to-answer | 26.0% | 28.0% | USD 579 mn | 7.3% |
By sales
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Instrument and reader placement | 26.0% | 24.0% | USD 579 mn | 5.7% |
| Test cassettes and panels | 66.0% | 68.0% | USD 1.5 bn | 6.8% |
| Software and service | 8.0% | 8.0% | USD 178 mn | 6.5% |
Top 25 countries for point-of-care respiratory diagnostic panels by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 88.0% of 2026 revenue and the 25 countries below together hold 96.4%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 1.1 bn | 50.0% | USD 2.1 bn | 6.5% |
| 2 | China | USD 223 mn | 10.0% | USD 501 mn | 8.5% |
| 3 | Germany | USD 111 mn | 5.0% | USD 188 mn | 5.4% |
| 4 | Japan | USD 111 mn | 5.0% | USD 188 mn | 5.4% |
| 5 | United Kingdom | USD 89 mn | 4.0% | USD 150 mn | 5.4% |
| 6 | France | USD 89 mn | 4.0% | USD 150 mn | 5.4% |
| 7 | Italy | USD 67 mn | 3.0% | USD 113 mn | 5.4% |
| 8 | Spain | USD 56 mn | 2.5% | USD 96 mn | 5.6% |
| 9 | Canada | USD 56 mn | 2.5% | USD 96 mn | 5.6% |
| 10 | Australia | USD 45 mn | 2.0% | USD 75 mn | 5.4% |
| 11 | Switzerland | USD 42 mn | 1.9% | USD 75 mn | 6.0% |
| 12 | Netherlands | USD 25 mn | 1.1% | USD 45 mn | 6.1% |
| 13 | South Korea | USD 18 mn | 0.8% | USD 33 mn | 6.1% |
| 14 | Belgium | USD 15 mn | 0.7% | USD 26 mn | 6.0% |
| 15 | Sweden | USD 12 mn | 0.6% | USD 23 mn | 6.1% |
| 16 | Mexico | USD 11 mn | 0.5% | USD 28 mn | 9.9% |
| 17 | Poland | USD 9.6 mn | 0.4% | USD 25 mn | 9.9% |
| 18 | India | USD 8.7 mn | 0.4% | USD 23 mn | 10.0% |
| 19 | Turkey | USD 8.0 mn | 0.4% | USD 20 mn | 9.8% |
| 20 | Austria | USD 7.3 mn | 0.3% | USD 13 mn | 6.2% |
| 21 | Taiwan | USD 6.9 mn | 0.3% | USD 13 mn | 6.2% |
| 22 | Brazil | USD 6.5 mn | 0.3% | USD 17 mn | 10.0% |
| 23 | Israel | USD 6.0 mn | 0.3% | USD 15 mn | 9.9% |
| 24 | Denmark | USD 5.8 mn | 0.3% | USD 10 mn | 6.1% |
| 25 | Saudi Arabia | USD 5.6 mn | 0.2% | USD 14 mn | 9.5% |
| Rest of world | USD 80 mn | 3.6% | USD 155 mn | 6.8% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Abbott
- Roche
- QuidelOrtho
- bioMérieux
- Cepheid
- Becton Dickinson
Group 2: Regional and specialist players
- Hologic
- SD Biosensor
- OraSure Technologies
- Qiagen
- DiaSorin
Group 3: Emerging and niche players
- Sekisui Diagnostics
- Coris BioConcept
- Talis Biomedical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the point-of-care respiratory diagnostic panels market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.5% is calculated from the resulting values.
The market is divided by test type, by setting, by pathogen, by format, by sales. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the point-of-care respiratory diagnostic panels market?
The global point-of-care respiratory diagnostic panels market is estimated at USD 2.1 bn in 2025 and USD 2.2 bn in 2026.
How fast will the point-of-care respiratory diagnostic panels market grow?
It is forecast to reach USD 4.2 bn by 2036, a compound annual growth rate of 6.5% from 2026, an increase of USD 2.0 bn.
Which country is the largest market for point-of-care respiratory diagnostic panels?
United States is the largest market by revenue at USD 1.1 bn in 2026, 50.0% of the global total. The three largest countries together hold 65.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 8.5% a year from 2026 to 2036.
Which point-of-care respiratory diagnostic panels segment is largest?
In the by test type split, Molecular multiplex panels is the largest segment with 36.0% of 2026 revenue.
Who are the leading point-of-care respiratory diagnostic panels companies?
Global leaders include Abbott, Roche, QuidelOrtho, bioMérieux.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Amniotic MembraneUSD 2.2 bn · 8.5% CAGR
- New Approach Methodologies Nonclinical TestingUSD 2.2 bn · 13.0% CAGR
- Medical CannulaUSD 2.3 bn · 5.3% CAGR
- Dental SterilizationUSD 2.0 bn · 6.0% CAGR
- Tangential Flow FiltrationUSD 2.5 bn · 9.0% CAGR
- Cardiovascular Drug DiscoveryUSD 2.6 bn · 7.5% CAGR
- Chromatography ResinUSD 2.6 bn · 9.8% CAGR
- 3D Cell CultureUSD 2.7 bn · 12.0% CAGR